logo-loader
viewSolGold plc

SolGold: Explorer may have found a "sleeping giant" within its portfolio of copper-gold assets in northern Ecuador

"Early work is revealing what we believe could be a sleeping giant with a big cluster of large and fertile porphyry systems similar to those discovered at the company's Cascabel project,” said Benn Whistler, SolGold’s technical manager, of Rio Amarillo.

SolGold plc -

SolGold plc (LON:SOLG), the mine exploration specialist with heavyweight backing, said it has identified what could be a "sleeping giant" within its portfolio of copper-gold assets in northern Ecuador.

The cluster of preserved porphyry lithocap zones has been discovered at the Rio Amarillo site, 35km from the company’s flagship Alpala copper, gold and silver discovery.

Porphyry deposits tend to be large, internationally-significant accumulations that are found in formerly volcanically active parts of the world such as Chile and Mongolia.

"Early work is revealing what we believe could be a sleeping giant with a big cluster of large and fertile porphyry systems similar to those discovered at the company's Cascabel project,” said Benn Whistler, SolGold’s technical manager, of Rio Amarillo.

The main target areas have characteristics typical of other similar systems and clusters of systems along the Andean Copper Belt that have generated some very “large globally significant porphyry deposits”, he added.

“With surface mineralisation covering a vertical extent of up to 1500m, we can envisage that exploratory drilling will test an enormous vertical column of 3-3.5km," he added.

SolGold’s made its name discovering Alpala, a world-class asset with contained metal content of 8.4 Mt of copper and 19.4mln ounces of gold in the indicated category.

Mining giant BHP (LON:BHP) is a 15% shareholder in the business.

Quick facts: SolGold plc

Price: 19.358 GBX

AIM:SOLG
Market: AIM
Market Cap: £372.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

18 hours, 5 minutes ago

2 min read